On the evening of September 7, the First International Biomedical Industry Innovation Beijing Forum held a "Cooperation Night". Beijing Yizhuang (Beijing Economic and Technological Development Zone) signed three major projects: innovation partner project, cutting- edge technology cooperation project, and advantageous platform cooperation project. There are a total of 18 projects in this category, with a total investment of nearly 3 billion RMB. It has cooperated with Bayer, Sanofi, and AstraZeneca, China
Biopharmaceuticals, the top 50 global Pharmaceutical Companies, a companies listed on the Science and Technology Innovation Board, and "Top 100 Enterprises in China's Pharmaceutical Industry". Others have joined hands to build a global "intelligent manufacturing of new drugs" industrial highland, adding "strong forces" to high-quality development.
Quinovare, which owns the world's largest and most complete needle-free automated production line, has become one of the first 18 projects signed by Yizhuang with its high-precision features.
Since its establishment in 2007,Quinovare has been deeply involved in needle-free drug delivery technology, and has devoted itself toresearching and designing needle- free injection delivery models that match various medication. It can now meet the precise delivery of different liquid medications in the skin, subcutaneously and into muscles. At present, clear clinical results have been achieved in the treatment of diabetes, childhood dwarfism, and vaccination.
Quinovare plans to build 6 new needle-free delivery consumables production lines and 2 needle-free injector automation production lines in the Economic Development Zone, with a total investment of 100 million yuan. And build a needle-free delivery technology platform for insulin, growth hormone,
vaccines and other drugs. Director Kong Lei of the Beijing Economic Development Zone Management Committee completed the signing with Zhang Yuxin, Chairman of Quinovare Company, on behalf of the Economic Development Zone.
In the future, Quinovare will move down-to-earth towards two key goals in the medical and health field:
First, based on the technology platform of precise injection fluid control, we will continue to achieve innovation in needle-free drug delivery systems, broaden the needle-drug integration model, and combine it with drugs in more fields to better achieve drug efficacy;
Second, promote the application of needle-free drug delivery, generally improve patient compliance, increase treatment accessibility, and gradually change the treatment scene from in-hospital to out-of-hospital, so that needle-free technology can be fully applied in families, and disease management can be achieved through needle-free digital systems. Full-cycle monitoring and treatment to improve patients’ quality of life.Quinovare will rely on the general environment of the "Intelligent Manufacturing of New Medication" industrial chain construction in the Yizhuang Economic Development Zone, take root in the Economic Development Zone, create a new drug delivery track, empower the biopharmaceutical industry, and contribute to the development of the Economic Development Zone.
Post time: Sep-21-2023